Literature DB >> 30640180

Effects of the α2/α3-subtype-selective GABAA receptor positive allosteric modulator KRM-II-81 on pain-depressed behavior in rats: comparison with ketorolac and diazepam.

Megan J Moerke1, Guanguan Li2, Lalit K Golani2, James Cook2, S Stevens Negus1.   

Abstract

This study examined effects of the α2/α3-subtype-selective GABAA receptor positive allosteric modulator KRM-II-81 in an assay of pain-related behavioral depression. Adult, male Sprague-Dawley rats responded for electrical brain stimulation in a frequency-rate intracranial self-stimulation (ICSS) procedure. Intraperitoneal injection of 1.8% lactic acid served as an acute noxious stimulus to depress ICSS. Effects of KRM-II-81 were evaluated in the absence and presence of the acid noxious stimulus. The NSAID ketorolac and the benzodiazepine diazepam were tested as comparators. Neither ketorolac nor KRM-II-81 altered ICSS in the absence of the acid noxious stimulus; however, diazepam produced facilitation consistent with its abuse liability. Ketorolac blocked acid-induced depression of ICSS, and effects of 1.0 mg/kg ketorolac lasted for at least 5 h. KRM-II-81 (1.0 mg/kg) produced significant antinociception after 30 min that dissipated by 60 min. Diazepam also attenuated acid-depressed ICSS, but only at doses that facilitated ICSS when administered alone. The lack of ketorolac or KRM-II-81 effects on ICSS in the absence of the acid noxious stimulus suggests low abuse liability for both compounds. The effectiveness of ketorolac to block acid-induced ICSS depression agrees with clinical analgesic efficacy of ketorolac. KRM-II-81 produced significant but less consistent and shorter-acting antinociception than ketorolac.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30640180      PMCID: PMC6610697          DOI: 10.1097/FBP.0000000000000464

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  5 in total

1.  Design, synthesis and characterization of novel gamma‑aminobutyric acid type A receptor ligands.

Authors:  Kamal P Pandey; Zubair Ahmed Khan; Lalit K Golani; Prithu Mondal; Yeunus Mian; Farjana Rashid; V V N Phani Babu Tiruveedhula; Daniel E Knutson; Dishary Sharmin; Taukir Ahmed; Sepideh Rezvanian; Nicolas M Zahn; Leggy A Arnold; Jeffrey M Witkin; James M Cook
Journal:  ARKIVOC       Date:  2020-12-02       Impact factor: 1.140

2.  The Positive Allosteric Modulator of α2/3-Containing GABAA Receptors, KRM-II-81, Is Active in Pharmaco-Resistant Models of Epilepsy and Reduces Hyperexcitability after Traumatic Brain Injury.

Authors:  Jeffrey M Witkin; Guanguan Li; Lalit K Golani; Wenhui Xiong; Jodi L Smith; Xingjie Ping; Farjana Rashid; Rajwana Jahan; Rok Cerne; James M Cook; Xiaoming Jin
Journal:  J Pharmacol Exp Ther       Date:  2019-11-06       Impact factor: 4.030

3.  Effects of repeated treatment with monoamine-transporter-inhibitor antidepressants on pain-related depression of intracranial self-stimulation in rats.

Authors:  L P Legakis; L Karim-Nejad; S S Negus
Journal:  Psychopharmacology (Berl)       Date:  2020-05-08       Impact factor: 4.530

4.  The α2,3-selective potentiator of GABAA receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats.

Authors:  J M Witkin; R Cerne; P G Davis; K B Freeman; J M do Carmo; J K Rowlett; K R Methuku; A Okun; S D Gleason; X Li; M J Krambis; M Poe; G Li; J M Schkeryantz; R Jahan; L Yang; W Guo; L K Golani; W H Anderson; J T Catlow; T M Jones; F Porreca; J L Smith; K L Knopp; J M Cook
Journal:  Pharmacol Biochem Behav       Date:  2019-02-27       Impact factor: 3.533

5.  Lack of effect of the nociceptin opioid peptide agonist Ro 64-6198 on pain-depressed behavior and heroin choice in rats.

Authors:  Megan Jo Moerke; S Stevens Negus; Matthew L Banks
Journal:  Drug Alcohol Depend       Date:  2021-12-30       Impact factor: 4.492

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.